NCT03037970 (ABSOLVE) is a Phase 2 clinical trial of RhPDGF-BB in Diabetic Foot Ulcers, sponsored by Lynch Biologics LLC.

Who is sponsoring NCT03037970?

NCT03037970 is sponsored by Lynch Biologics LLC.

What drugs are being tested in NCT03037970?

Interventions in NCT03037970: RhPDGF-BB, Placebo.

What condition does NCT03037970 study?

NCT03037970 studies Diabetic Foot Ulcers.

Is NCT03037970 still recruiting?

NCT03037970 is currently status unknown. Last updated 31 January 2017.

Last reviewed 2017-01-31 · How we verify

NCT03037970: ABSOLVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of ABSOLVE in Diabetic Foot Ulcers

Status unknown Phase 2 Last updated 31 January 2017

What this trial tests

Phase 2 trial testing RhPDGF-BB in Diabetic Foot Ulcers in 40 participants. Status unknown.

Timeline

30 January 2017

Primary endpoint
15 August 2017

15 October 2017

Quick facts

Lead sponsor	Lynch Biologics LLC
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	30 January 2017
Primary completion	15 August 2017
Estimated completion	15 October 2017
Sites	1 location across Guatemala

Drugs / interventions tested

RhPDGF-BB — full drug profile →
Placebo

Conditions studied

Diabetic Foot Ulcers — all drugs for Diabetic Foot Ulcers →

Sponsor

Lynch Biologics LLC — full company profile →

Who can join

Adults 30 to 75, any sex, with Diabetic Foot Ulcers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ABSOLVE Biologic Wound Matrix is a combination of recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a bovine type I collagen wound dressing matrix. ABSOLVE is under development for the treatment of chronic and acute wounds. This study investigates the safety and efficacy of ABSOLVE in chronic diabetic foot ulcers (DFUs).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bioactive peptides and proteins for tissue repair: microenvironment modulation, rational delivery, and clinical potential.
Hao ZW, Zhang ZY, Wang ZP, Wang Y, et al · · 2024 · cited 24× · PMID 39639374 · DOI 10.1186/s40779-024-00576-x

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcers

Currently open trials in the same condition.

NCT06189638 — Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03037970 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lynch Biologics LLC
Last refreshed: 31 January 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03037970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing